Editas Medicine Dividend
Dividend criteria checks 0/6
Editas Medicine does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.8% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | US$0 |
| Earnings per share | -US$3.27 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06Editas: The Unforeseen Detrimental Effect Of Patent Win
Mar 25Editas: CRISPR Gene Editing Biotech With Promising Future
Mar 15Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
Feb 25Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently
Dec 28Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles
Dec 15Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Nov 17Editas: Data Was Eagerly Anticipated But Failed To Impress
Nov 03Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?
Sep 07Editas: Gene Therapy Specialist Leading The Way In Eye Disease
Aug 27Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Aug 12Editas Medicine: An Undervalued, Gene-Editing Stock
Jul 01Editas Medicine Q1 2021 Earnings Preview
May 04We're Not Very Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate
Apr 29Chairman James Mullen Just Bought 250% More Shares In Editas Medicine, Inc. (NASDAQ:EDIT)
Mar 05Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 11%
Feb 27Could The Editas Medicine, Inc. (NASDAQ:EDIT) Ownership Structure Tell Us Something Useful?
Feb 12What Does The Future Hold For Editas Medicine, Inc. (NASDAQ:EDIT)? These Analysts Have Been Cutting Their Estimates
Jan 21
This Insider Has Just Sold Shares In Editas Medicine, Inc. (NASDAQ:EDIT)
Jan 15Stability and Growth of Payments
| Month | Dividend Per Share (annual) | Avg. Yield (%) |
|---|---|---|
| 12/31/2025 | - | 0% |
| 12/31/2024 | - | 0% |
| 12/31/2023 | - | 0% |
Stable Dividend: Insufficient data to determine if EDIT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EDIT's dividend payments have been increasing.
Dividend Yield vs Market
| Editas Medicine Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (EDIT) | n/a |
| Market Bottom 25% (US) | 1.7% |
| Market Top 25% (US) | 5.2% |
| Industry Average (Biotechs) | 2.8% |
| Analyst forecast in 3 Years (EDIT) | 0% |
Notable Dividend: Unable to evaluate EDIT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EDIT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EDIT has not reported any payouts.